Role of ‘Spot Sign’ on CT Angiography to Predict Hematoma Expansion in Spontaneous Intracerebral Hemorrhage

Soo Yong Park, M.D.; Min Ho Kong, M.D.; Jung Hee Kim, M.D.; Dong Soo Kang, M.D., Ph.D.; Kwan Young Song, M.D.; Seung Kon Huh, M.D., Ph.D.
Department of Neurosurgery, Seoul Medical Center, Seoul, Korea
Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea

Objective: Patients with spontaneous intracerebral hemorrhage (ICH) presenting within 24 hours of symptom onset are known to be increased risk of hematoma expansion which is closely correlated with morbidity and mortality. We investigated whether tiny enhancing foci (‘Spot sign’) on axial view of 3-dimensional computed tomography angiography (3D-CTA) source images can predict subsequent hematoma expansion in spontaneous ICH.

Methods: During a 2-year period (March 2007-March 2009), we prospectively evaluated 3D-CTA of 110 patients with spontaneous ICH. Based on source images of 3D-CTA, patients were classified according to presence or absence of ‘Spot sign’; ‘Spot sign’ (+) group, ‘Spot sign’ (-) group. Radiological factors and clinical outcomes were compared between two groups.

Results: Hematoma expansion occurred in 16 patients (15%). Mean Glasgow Coma Scale (GCS) score of patients with hematoma expansion was significantly different compared to scores of patients without hematoma expansion (5 vs. 9, p < 0.001). Nineteen patients (16%) of 110 ICH patients demonstrated ‘spot sign’ on 3D-CTA. Among the ‘spot sign’ (+) group, 53% of patients developed hematoma expansion. Conversely, 7% of patients without ‘spot sign’ demonstrated the hematoma expansion (p < 0.001). Initial volume and location of hematoma were significantly not associated with hematoma expansion except shape of hematoma.

Conclusion: Our study showed that patients with hematoma expansion of spontaneous ICH had significant clinical deterioration. And the fact that ‘spot sign’ (+) group have higher risk of hematoma expansion suggests the presence of ‘spot sign’ on source images of 3D-CTA can give a clue to predict hematoma expansion in spontaneous ICH.

KEY WORDS: Intracerebral hemorrhage • Computed tomography angiography • Hematoma expansion • Prognosis.

INTRODUCTION

Spontaneous intracerebral hemorrhage (ICH) is defined as spontaneous, nontraumatic bleeding into the parenchyma of the brain. It is responsible for 10-15% of stroke cases in the US populations and up to 20-30% in Asian group. And, the outcome of ICH is significantly worse than with that of ischemic stroke, with up to 50% mortality at 30 days. Recent reports confirmed that morbidity and mortality in spontaneous ICH are correlated with hematoma expansion. In order to treat acute ICH effectively and properly, it is important to identify and predict which patients would develop hematoma expansion.

Hypertension, diabetes mellitus, liver disease, amyloid angiopathy, and coagulopathy have been regarded as risk factors of hematoma expansion. Other known clinical risk factors for hematoma expansion include both antecedent warfarin use and ultra-early presentation. Unfortunately, in most patients with ICH there are no established markers for identifying patients with risk of expansion. Thus, accurate and reliable predictors of hematoma expansion are needed for better outcome.

Computed tomography angiography (CTA) is a rapid, noninvasive investigation for patients with ICH and has been proven useful for identifying potentially treatable entities such as aneurysms and other vascular lesions. Various
analyses and investigations to validate its usefulness have also been reported recently. In this study, we investigated the incidence of 'spot sign' at spontaneous ICH and analyze the correlation between a 'spot sign' and hematoma expansion.

**MATERIALS AND METHODS**

**Patients**

Between March 1st 2007 and March 31st 2009, we prospectively studied patients with spontaneous ICH visited at our institution within 24 hours of symptom onset. These consecutive patients with spontaneous ICH who underwent a standard CT protocol were enrolled in our database. Patients were excluded if ICH was secondary to head trauma, ischemic stroke with hemorrhagic transformation, tumor, vascular malformation, or cerebral aneurysm. All patients were evaluated with brain computed tomography (CT) scans and 3D-CTAs within 24 hours of symptom onset. Also, all patients were evaluated with at least one more brain CT scan within 48 hours after their 3D-CTA.

According to the study design, 110 patients were included and 69 patients (63%) were male. The median age was 62 years (range, 33 to 88 years). Clinical data were collected by 2 neurosurgeons during admission period.

**Clinical parameters**

All subjects and their family members were interviewed for clinical data including history of hypertension, diabetes mellitus, coronary artery disease, and medications. Patient's data were classified by the factors of sex, age, smoking or alcohol history, and other factors. Laboratory studies including serum glucose, platelet count, and normalized ratio of the prothrombin time were taken at the time of admission. The first documented systolic blood pressure (SBP) and diastolic blood pressure (DBP) were taken as admission SBP and DBP. Admission Glasgow Coma Scale (GCS) score was measured immediately after arrival at emergency room. Time of symptom onset was defined as the last time the patient was known to be symptom free.

**Brain CT protocol**

First, non-enhanced brain CT scan, as an initial baseline study, was performed using a helical CT scanner (Somatom Sensation 64; Siemens Medical Solutions USA, Inc. Malvern, Pennsylvania, USA). This was followed by helical scanning during the administration of 100 mL of nonionic contrast agent (Ultrasite®, Bayer Healthcare Pharmaceuticals, Inc., Nordrhein-Westfalen, Germany) at 3 to 5 mL/second with a 25 to 40 second prep delay using standard scan parameters of 120 kVp and 200 mAs. Section thickness was 5 mm for non-enhanced scans and 3D-CTA. Also, 48 hours after the initial brain CT scan, follow-up brain CT scan was performed.

**Hematoma expansion**

Volume of ICH was determined from baseline brain CT scans with ABC/2 method. Hematoma expansion within 48 hours was defined by an increase in volume of > 30% or > 6 mL from baseline brain CT scan by the criteria of Wada et al. Volumes of ICH were compared between the brain CT performed at the time of 3D-CTA and the last brain CT performed up to 48 hours after 3D-CTA. Images were electronically transferred in DICOM (digital imaging and communication in medicine) format to a workstation for analysis (Marosis Marview software; Marotech, Inc. Seoul, Korea). Location of hematoma was classified as basal ganglia, thalamus, lobar, cerebellum, pons and multiple types. Shape of hematoma was classified as round, ovoid and irregular. Clinical deterioration was defined by aggravation of consciousness disturbance or neurologic deficits including motor deficits and cranial nerve palsy.

**Spot sign**

All studies were prospectively evaluated for the presence or
the absence of 'spot sign' on 3D-CTA[11]. 'Spot sign' was defined as 1 or more 1- to 2-mm sized foci of enhancement within hematoma on axial view of 3D-CTA source images (Fig. 1). An ovoid or round shape of foci was also included as 'spot sign'. The location of 'spot sign' was inspected as a center of hematoma or peripheries of hematoma. We excluded the foci which was located outside the hematoma. By the definition of 'spot sign', foci of enhancement within hematoma on axial view of 3D-CTA source images were divided as 'spot sign' (+) group and 'spot sign' (-) group. Clinical and radiological factors and outcomes were compared between 'spot sign' (+) group and 'spot sign' (-) group.

Data analysis
A total of 110 patients were grouped by presence of 'spot sign'. The factors and outcomes of clinical, radiological values were analyzed by using the SPSS/PC statistical program (version 12.0 for windows; SPSS, Inc). Results were given as mean ± standard deviation values. Mean of age, initial GCS score, initial volume of hematoma, systolic blood pressure were calculated in each groups. Two-tailed Student's t-tests were used to calculate p values of these parameters. Factors including sex, smoking, alcohol abuse and history of diabetes mellitus and hypertension were recorded according to the groups. Chi-square tests were used to calculate p values of these parameters. Radiological and clinical outcomes between 'spot sign' (+) group and 'spot sign' (-) group were also given as mean ± standard deviation values. Mortality rate was calculated by results of survival of patients of each group in 3 months.

RESULTS

Incidence of hematoma expansion
According to follow-up brain CT scans, hematoma expansion in spontaneous ICH occurred in 16 patients (14.5%).

Clinical outcome according to presence of hematoma expansion
After hematoma expansion, mean GCS scores of patients with hematoma expansion were significantly different compared with the scores with the patients of non-hematoma expansion (GCS score 5 vs. 9, p <0.001). Clinical deterioration was not seen in 3 patients (19%) of hematoma expansion group (Table 1). In these patients, mass effects were not observed from the CT scans after hematoma expansion due to cerebral atrophy. Clinical deterioration occurred in 16 patients (17%) of non-hematoma expansion group. Eleven of them were diagnosed as hydrocephalus at the time of clinical deterioration. Five patients were associated with cerebral edema when clinical deterioration was observed.

Two group comparison according to presence or absence of 'spot sign'
Nineteen (17%) patients of spontaneous ICH demonstrated "spot sign" (Table 2). Initial mean GCS score was not significantly different between 'spot sign' (+) group and 'spot sign' (-) group. The baseline characteristics including mean age, gender, history of hypertension or diabetes mellitus, SBP, INR, and history of anticoagulants, smoking, alcohol abuse of the groups with and without 'spot sign' were not different statistically. Initial volume of hematoma of 'spot sign' (+) group (24.68 ± 23.99 cm³) was less than the volume of 'spot sign' (-) group (27.40 ± 32.82 cm³). Initial volume of hematoma was not associated with hematoma expansion.

Two group comparison according to presence or absence of 'spot sign'
In each group, 53% of patients with 'spot sign' and 7% of

<table>
<thead>
<tr>
<th>Table 1. Number of patients with clinical deterioration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

*Hematoma expansion was defined by an increase in volume of ≥ 33% or > 8 mL from baseline within 48 hours of computed tomography angiography. 1Clinical deterioration means an aggravation of consciousness disturbance or neurological deficits during 48 hours from the onset of hemorrhage, which was judged from medical records.

<table>
<thead>
<tr>
<th>Table 2. Clinical factors of patients with or without Spot Sign</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variables</td>
</tr>
<tr>
<td>Age (mean, yrs)</td>
</tr>
<tr>
<td>Gender (M : F)</td>
</tr>
<tr>
<td>GCS score, Mean*</td>
</tr>
<tr>
<td>Volume of hematoma (cm³)</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
</tr>
<tr>
<td>INR, mean</td>
</tr>
<tr>
<td>Personal history</td>
</tr>
<tr>
<td>History of HTN</td>
</tr>
<tr>
<td>History of DM</td>
</tr>
<tr>
<td>Smoking</td>
</tr>
<tr>
<td>Alcohol abuse</td>
</tr>
</tbody>
</table>

*Initial Glasgow Coma Score and systolic blood pressure were collected by medical records. Alcohol abuse was defined by history of medical treatment or objective symptoms (delirium, hallucinations, insomnia, etc.). GCS: Glasgow Coma Scale, SBP: systolic blood pressure, INR: international normalized ratio.
patients without 'spot sign' demonstrated the hematoma expansion (p < 0.001). Mean admission period was 47.37 ± 13.66 days in 'spot sign' (+) group and 37.11 ± 14.55 days in 'spot sign' (-) group, respectively (p < 0.001) (Table 3). The mortality rate during 3 months of admission period was 40.5% and 13.4% in each group, respectively (p < 0.001).

Shape and location of ICH

Table 3. Radiological and clinical outcomes in intracerebral hemorrhage patients with and without spot sign

<table>
<thead>
<tr>
<th>Variable</th>
<th>Spot sign</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive (n = 19)</td>
<td>Negative (n = 91)</td>
<td></td>
</tr>
<tr>
<td>Significant hematoma expansion</td>
<td>10 (53%)</td>
<td>6 (7%)</td>
</tr>
<tr>
<td>Mean volume change (cm3) *</td>
<td>22.68 ± 9.54</td>
<td>0.87 ± 4.17</td>
</tr>
<tr>
<td>Admission period (day)</td>
<td>47.37 ± 13.66</td>
<td>37.11 ± 14.55</td>
</tr>
<tr>
<td>Mortality rate *</td>
<td>40.5%</td>
<td>13.4%</td>
</tr>
</tbody>
</table>

*Mean volume change was calculated by the volume differences on brain computed tomography scan between initial images and follow-up images. *Mortality rate was estimated during 3 months of admission period.

Table 4. The incidence of hematoma expansion among locations of intracerebral hemorrhage

<table>
<thead>
<tr>
<th>Site of Hematoma</th>
<th>No. of cases</th>
<th>Hematoma expansion</th>
<th>Spot sign</th>
<th>Rate of expansion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal Ganglia</td>
<td>49 (44.5%)</td>
<td>9</td>
<td>40</td>
<td>8 41</td>
</tr>
<tr>
<td>Thalamus</td>
<td>20 (18.1%)</td>
<td>4</td>
<td>16</td>
<td>4 16</td>
</tr>
<tr>
<td>Subcortex</td>
<td>21 (19%)</td>
<td>1</td>
<td>20</td>
<td>5 16</td>
</tr>
<tr>
<td>Pons</td>
<td>8 (7.2%)</td>
<td>1</td>
<td>7</td>
<td>1 7</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>4 (3.6%)</td>
<td>0</td>
<td>4</td>
<td>0 4</td>
</tr>
<tr>
<td>Multiple</td>
<td>8 (7.2%)</td>
<td>1</td>
<td>7</td>
<td>1 7</td>
</tr>
<tr>
<td>Totals</td>
<td>110 (100%)</td>
<td>16</td>
<td>94</td>
<td>19 91</td>
</tr>
</tbody>
</table>

Irregular shape of hematoma was present in 19 patients in spontaneous ICH on initial presentation. Eleven patients (70%) with hematoma expansion and 8 patients (9%) without hematoma expansion showed irregular shape of hematoma on initial brain CT scans, respectively. Irregular shape of hematoma was showed significant association with hematoma expansion (p < 0.001).

DISCUSSION

Spontaneous ICH is responsible for 20% to 30% of all strokes, and mortality exceeds 50%. The incidence doubles with each decade of life above 45 years. It can cause severe, permanent neurologic deficits and complica-
tions with just a single attack. In addition, hematoma expansion is the main cause of mortality and morbidity of spontaneous ICH after hospitalization. Hematoma expansion can persist for up to 6 hours postictus. Several authors have reported that the bleeding can continue even later during the treatment course in some patients with spontaneous ICH. Continued bleeding may lead to expansion of an existing hematoma, resulting in progressive neurological deterioration.

In our study, 16 of 110 patients showed hematoma expansion. Thirteen patients (81%) of them experienced clinical deterioration including disturbance of consciousness and motor deficits. But, in 94 patients without hematoma expansion, clinical deterioration was occurred only in 16 patients (17%). Thus, this study results confirmed, as speculated, that hematoma expansion is a crucial risk factor of clinical outcome in spontaneous ICH.

The risk factors for hematoma expansion in ICH have been investigated by many researchers previously. On several studies, blood pressure had been regarded as the most important risk factor for acute stage hematoma expansion in spontaneous ICH. Kazuhiro et al. reported that elevated blood pressure increases the risk of hematoma expansion and that an effort to lower systolic blood pressure below 150 mmHg may prevent this risk. Kazui et al. reported that although it remained controversial whether antihypertensive drugs should be used in the acute phase of intracerebral hemorrhage, poorly controlled diabetics with high systolic blood pressure (>200 mmHg) on admission also were at high risk of hematoma enlargement. In our study, mean systolic blood pressure were relatively higher than normal range of systolic blood pressure. But, we could not find any significant differences in systolic blood pressure during admission period between those with hematoma expansion and those without hematoma expansion. Thus, systolic blood pressure was not a definite predictive risk factor of hematoma expansion in our study.

In the hyperacute stage of spontaneous ICH, reported risk factors associated with hematoma expansion include liver dysfunction, excessive alcohol consumption, anticoagulant therapy, thrombocytopenia. Yukihiko et al. reported that liver dysfunction was an important factor influencing hematoma volume and concluded that patients with liver dysfunction and coagulation abnormalities should be closely observed for at least 6 hours after onset before surgery. Since the risk of hematoma expansion in these circumstances is high. Akikazu et al. hypothesized that an impaired coagulation system facilitates hematoma expansion in spontaneous ICH. Plasma levels of both fibrinopeptide A and thrombin-antithrombin complex were statistically analyzed between hematoma expansion group and non-expansion group. Their results showed that coagulation system seemed to be highly activated depending on the hemorrhage volume within 3 hours after ictus and the hematoma expansion seemed to be occurred when thrombin generation was not sufficient after bleeding. They reported that plasma levels of the coagulation markers on admission could be useful predictors of the possible hematoma expansion which may lead to a poor outcome. However, Kim et al. reported that liver dysfunction and platelet count were not associated with hematoma expansion. Lim et al. studied about risk factors such as age, sex, blood pressure, history of diabetes mellitus, liver disease and hypertension. In our study, patient's previous history of liver disease and alcohol abuse were not statistically different between the hematoma expansion group and group without hematoma expansion. Furthermore, the laboratory results such as aspartate aminotransferase (AST)/alanine aminotransferase (ALT) and other liver function markers were not related with international normalized ratio (INR), prothrombin time (PT)/activated Partial thromboplastin time (aPTT) level nor hematoma expansion significantly. Although our study did not reveal the relationship between liver function markers, coagulation markers and hematoma expansion in spontaneous ICH patients, the risk of hematoma expansion in patients of liver disease and coagulopathy is unclear.

Initial GCS score was also concerned as one of the predictive risk factors of hematoma expansion. Our findings of initial GCS score between patients with hematoma expansion and without hematoma expansion did not show as an indicator of hematoma expansion. Initial GCS score has been known to be associated with patients' clinical outcome regardless of hematoma expansion rather than risk factor of hematoma expansion.

It has been hypothesized by many that certain shape of the hematoma, volume of hematoma and location of hematoma on initial CT scans are associated with presence of hematoma expansion. Yukihiko et al. studied that ICH patients with irregularly shaped large hematomas should be closely observed because of high risk of hematoma expansion. But, other studies reported that these factors do not influence hematoma expansion statistically. Several studies showed that the volume or location of hematoma did not lead to hematoma expansion frequently. Also, initial volume and location of hematoma did not correlate with hematoma expansion in our study. The shape of hematoma may be related with small vessel injury or coagulopathies and liver disease. In our study, the shape of hematoma was considered somehow meaningful as a risk factor of hematoma expansion. In particular, patients with irregular shape of
hematomas tended to have hematoma expansion more frequently. It can be explained that irregularly shaped hematomas may be resulted by actively bleeding from multiple arterioles. But, these results are not statistically significant and large-scaled studies are needed.

Recently, many reports concluded that extravasation on cerebral angiography is a useful marker of determining and identifying active bleeding. Goldstein et al. reported that contrast extravasations was independently associated with continued bleeding on spontaneous ICH and this effect was independent of time to presentation. Becker et al. showed that contrast extravasations into hematoma was associated with increased fatality and the risk of contrast extravasations was increased with hypertension, depressed consciousness, enlarged hematoma.

When cerebral angiography is not available in emergency circumstances, structural causes of hemorrhage can not be detected on routine CT scanning, including bleeding from a cerebral aneurysm or a vascular malformation. Recently, 3D-CTA is regarded as a highly sensitive modality for determining the source of hemorrhage. As 3D-CTA is being developed rapidly especially in resolution qualities, the source images of 3D-CTA could give us many information about small vessel injuries and anomalies as well as cerebral aneurysm like lesions. Thus, we included 3D-CTA as a routine modality in spontaneous ICH.

In the absence of an underlying aneurysm or aneurysm-like lesions on 3D-CTA, the peripheral enhancement on source images of 3D-CTA supports the assertion that these foci represent active hemorrhage from secondary damaged or torn perforations. As a result, recent focus of radiologic markers in spontaneous ICH represents the enhancing foci. Recent studies concluded that 'spot sign' is regarded as tiny, enhancing foci within hematomas on 3D-CTA source images. We defined 'spot sign' as 1 or more 1- to 2-mm sized foci of enhancement within the hematoma on axial section of 3D-CTA source images. These signs are with clear contrast extravasations in CTA. As 3D-CTA is used conventionally in most stroke centers, various data of 'spot sign' on source images of 3D-CTA can be analyzed in many ways. Because 'spot sign' is considered as small vessel injuries, it was hoped that hematoma expansion could be predicted by the presence of 'spot sign'. We therefore assessed the effectiveness of 'spot sign' in estimation of hematoma expansion on the acute stage of spontaneous ICH.

As our results of analysis between 'spot sign' (+) group and 'spot sign' (-) group, 'spot sign' itself seemed to raise the risk of hematoma expansion. And, clinical outcomes of 'spot sign' (+) group were significantly different with that of 'spot sign' (-) group. Mean admission period of 'spot sign' (+) group was 47.37 days, whereas that of 'spot sign' (-) group was 37.11 days. Mortality rate between two groups were also statistically different (40.5%, 13.4%, respectively). As seen in relationship of 'spot sign' and hematoma expansion, 'spot sign' could be a reliable radiologic predictor of clinical deterioration and poor outcomes in spontaneous ICH. Also, using source images of 3D-CTA in analysis, results of our study could be useful in clinical management based on its feasibility and affordability, especially in time course of treatment.

There are some limitations of our study to confirm 'spot sign' as a universal radiologic marker. Even though many radiologists defined 'spot sign' precisely, it is not absolutely objective but rather subjective. The authors tried to define 'spot sign' strictly in many points such as location, shape, number of this sign. Further study is required to define more precisely in objective way. Further improvement in resolution of 3D-CTA will be useful in this regard. Also, pathological characteristics of hematoma between 'spot sign' (+) group and 'spot sign' (-) group should be investigated in further studies. Our study data consisted of only 110 patients with spontaneous ICH, and patients of hematoma expansion and 'spot sign' was also relatively low in numbers.

CONCLUSION

The patients with hematoma expansion of spontaneous ICH showed significant clinical deterioration. Since 'spot sign' (+) group was associated with higher risk of hematoma expansion, its presence on axial sections of 3D-CTA source images at initial presentation can be considered as a one of useful predictors for possible subsequent hematoma expansion.

Acknowledgements

We thank Dr. Jaeg Se Youn and Dr. Huh Hoon in Seoul Medical Center for their faithful assistance to keep this enormous survey going.

References


